undamentalytics Newsletter
Sign in

Coherus Oncology, Inc. balance sheet

At the end of fiscal 2025, Coherus Oncology, Inc. had total assets of $258m, total liabilities of $197m and shareholders' equity of $61.0m. It held $88.9m in cash against $0 of debt: net cash of $88.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents154015015812512772178541417641031268983
Receivables—0222—01421571231102611111814
Inventory——————21044383963436
Total current assets—4617919716114584343767602381476342207134
Goodwill——1111111111———
Total assets—4718721217816399409842679481630449258191
Accounts payable—39262015152615161235281013
Deferred revenue (current)—1423501——————————
Total current liabilities—545210656283311514616513933228314076
Long-term debt————75760748081—————
Total debt0100757677798081—0000
Total liabilities—90120219159132138304561582618823581197130
Shareholders' equity−46−9767−62131−3910528198−137−193−1326161
Non-controlling interests and other (assets − liabilities − equity)—55—————————————
Net debt (negative = net cash)−15−38−150−158−50−515−99−461−336−64−103−126−89−83
Shares outstanding———39m46m60m68m70m73m77m79m112m116m121m154m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CHRS vs OCULCHRS vs GOSSCHRS vs SIGA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coherus Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coherus Oncology, Inc.